As the pan-European STOXX Europe 600 Index remains steady, investors are closely watching interest rate policies and trade dynamics that continue to shape market sentiment. In this context, penny stocks—though an older term—still capture the essence of smaller or less-established companies that may offer significant value opportunities. By identifying those with solid financials and growth potential, investors can uncover promising options within this often-overlooked segment of the market.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.216 | €1.46B | ✅ 5 ⚠️ 2 View Analysis > |
| Lucisano Media Group (BIT:LMG) | €1.11 | €16.49M | ✅ 3 ⚠️ 4 View Analysis > |
| Maps (BIT:MAPS) | €3.24 | €43.03M | ✅ 5 ⚠️ 1 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €224.95M | ✅ 2 ⚠️ 2 View Analysis > |
| Hove (CPSE:HOVE) | DKK4.49 | DKK113.52M | ✅ 2 ⚠️ 2 View Analysis > |
| Siili Solutions Oyj (HLSE:SIILI) | €4.85 | €39.33M | ✅ 3 ⚠️ 3 View Analysis > |
| Hifab Group (OM:HIFA B) | SEK3.44 | SEK209.29M | ✅ 2 ⚠️ 2 View Analysis > |
| Nurminen Logistics Oyj (HLSE:NLG1V) | €1.04 | €83.92M | ✅ 3 ⚠️ 2 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.20 | €304.09M | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 270 stocks from our European Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Deceuninck (ENXTBR:DECB)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Deceuninck NV designs, manufactures, recycles, and distributes multi-material window, door, and building solutions across Europe, North America, Turkey, and internationally with a market cap of €304.09 million.
Operations: The company's revenue is primarily derived from its Window and Door Systems segment, which accounts for €724.41 million, followed by Home Protection at €38.30 million and Outdoor Living at €26.26 million.
Market Cap: €304.09M
Deceuninck NV's recent earnings report highlights a significant turnaround, with net income rising to €11.15 million for the first half of 2025, up from €7.74 million the previous year, despite a decline in sales to €383.55 million from €421.57 million. This growth is supported by an impressive earnings increase of over 800% last year and strong financial health with short-term assets exceeding liabilities and well-covered interest payments on debt. However, challenges include a relatively inexperienced management team and low return on equity at 5.7%, alongside an unstable dividend track record which may concern some investors seeking consistent returns.
- Dive into the specifics of Deceuninck here with our thorough balance sheet health report.
- Learn about Deceuninck's future growth trajectory here.
Nurminen Logistics Oyj (HLSE:NLG1V)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Nurminen Logistics Oyj offers logistics services across Finland, Russia, Sweden, and the Baltic countries with a market cap of €83.92 million.
Operations: The company's revenue is primarily derived from its Transportation - Trucking segment, which generated €107.40 million.
Market Cap: €83.92M
Nurminen Logistics Oyj has shown a positive shift in its financial performance, reporting net income of €1.47 million for Q2 2025 compared to a loss the previous year, with sales reaching €27.93 million. The company's debt levels are satisfactory, with operating cash flow covering 52.9% of its debt and interest payments well covered by EBIT at 4.7 times. Despite past negative earnings growth, Nurminen's return on equity is high at 33.2%, and it trades significantly below estimated fair value. However, short-term assets do not cover long-term liabilities, posing potential financial challenges ahead.
- Take a closer look at Nurminen Logistics Oyj's potential here in our financial health report.
- Understand Nurminen Logistics Oyj's earnings outlook by examining our growth report.
Acarix (OM:ACARIX)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Acarix AB (publ) is a medical device company that develops AI-based solutions for the rapid rule-out of coronary artery disease, with a market cap of SEK335.31 million.
Operations: The company generates revenue from its Diagnostic Kits and Equipment segment, amounting to SEK5.56 million.
Market Cap: SEK335.31M
Acarix AB is navigating the European penny stock landscape with a focus on AI-driven diagnostic solutions, but faces challenges typical of its category. Despite recent advancements in U.S. reimbursement processes for its CADScor device and entry into the MENA market with a SEK1.35 million order, Acarix remains pre-revenue, reporting sales of SEK2.87 million for the first half of 2025. The company is unprofitable and has less than a year of cash runway, though it benefits from being debt-free and having short-term assets exceeding liabilities. Management's limited experience may impact strategic execution as they aim for financial stability amidst high share price volatility.
- Click here to discover the nuances of Acarix with our detailed analytical financial health report.
- Evaluate Acarix's prospects by accessing our earnings growth report.
Turning Ideas Into Actions
- Explore the 270 names from our European Penny Stocks screener here.
- Ready To Venture Into Other Investment Styles? Uncover 11 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Acarix might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com